Application of an Electronic Nose in the Early Detection of ASpergillosis

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)52 enrolled

Overview

The purpose of this study is to establish the accuracy with which the eNose can discriminate patients with invasive pulmonary aspergillosis from controls.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pulmonary Invasive Aspergillosis

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Patients that 1. are 18 years of age or older 2. will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia (according to CTCAE 3.0, i.e. \<0.5 x 109 neutrophils/L) of prolonged duration (i.e., more than 7 days), e.g. hematopoietic stem cell transplantation or induction/consolidation treatment for acute myeloid leukaemia 3. have given written informed consent Exclusion Criteria: 1. a previously diagnosed invasive mycosis 2. the inability to perform the breathing manoeuvre needed for eNose-analysis of exhaled air

Locations (1)

Department of Hematology, Academic Medical Center

Amsterdam, Netherlands

Outcomes

Primary Outcomes

accuracy with which the Cyranose can discriminate between patients with probable or proven invasive pulmonary aspergillosis and neutropenic controls with fever

The cross-validated accuracy with which the Cyranose can discriminate between patients with probable or proven invasive pulmonary aspergillosis and neutropenic controls with fever, defined as the percentage of correctly classified patients using the leave-one out method

Time frame: 4 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.